NeoGenomics, Inc. (NEO)
Price:
11.86 USD
( + 0.09 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
IDEXX Laboratories, Inc.
VALUE SCORE:
8
2nd position
GRAIL, Inc.
VALUE SCORE:
9
The best
Medpace Holdings, Inc.
VALUE SCORE:
9
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NEWS
NeoGenomics to Present New ctDNA Research at SABCS 2025
businesswire.com
2025-12-10 07:05:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.
AerCap Signs Lease Agreements with New Customer My Freighter for Two New Airbus A321NEO Aircraft
prnewswire.com
2025-12-09 04:00:00DUBLIN , Dec. 9, 2025 /PRNewswire/ -- AerCap Holdings N.V. ("AerCap" or the "Company") (NYSE: AER) today announced it has signed lease agreements for two new Airbus A321neo aircraft with My Freighter, an Uzbekistan-based cargo airline that also operates charter and scheduled passenger services as Centrum Air.
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
businesswire.com
2025-12-08 08:05:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.
UK: TotalEnergies Merges Its Upstream Business with NEO NEXT, Creating the Largest Independent Oil and Gas Producer in the UK
businesswire.com
2025-12-08 03:08:00PARIS--(BUSINESS WIRE)--TotalEnergies has signed an agreement with NEO NEXT Energy Limited (NEO NEXT) under which TotalEnergies will merge its Upstream business with NEO NEXT and become the leading shareholder in the expanded NEO NEXT, which will be renamed NEO NEXT+, with a 47.5% ownership. After completion of the transaction, NEO NEXT+ will: be jointly owned by TotalEnergies (47.5%), HitecVision (28.875%) and Repsol UK (23.625%) and encompass a large and diverse asset portfolio including nota.
Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $13.11
defenseworld.net
2025-11-18 02:34:45Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) have earned an average rating of "Hold" from the sixteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company.
Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-14 12:41:31Neo Performance Materials Inc. ( NEO:CA ) Q3 2025 Earnings Call November 14, 2025 10:00 AM EST Company Participants Karen Murray Rahim Suleman - CEO, President & Director Jonathan Baksh - Executive VP & CFO Conference Call Participants Daniel Harriman - Sidoti & Company, LLC Nicholas Boychuk - Cormark Securities Inc., Research Division Ian Gillies - Stifel Nicolaus Canada Inc., Research Division Presentation Operator Good morning, and welcome to the Neo Performance Materials Third Quarter 2025 Earnings Conference Call. For opening remarks and introduction, let me turn the call over to Karen Murray, General Counsel for Neo.
NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)
globenewswire.com
2025-11-13 09:00:00CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial.
NeoGenomics to Participate in Upcoming Investor Conferences
businesswire.com
2025-11-06 07:05:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 37th Annual Healthcare Conference.
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
businesswire.com
2025-10-30 12:51:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research at ISLB 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 MRD assays, plus four additional posters.
NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-10-28 15:11:55NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Priya Vedaraman Anthony Zook - CEO & Director Jeffrey Sherman - Chief Financial Officer Warren Stone - President & COO Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Mason Carrico - Stephens Inc., Research Division Thomas Stevens - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Yuko Oku - Morgan Stanley, Research Division Puneet Souda - Leerink Partners LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Joseph Conway - Needham & Company, LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the NeoGenomics Third Quarter 2025 Financial Results Call.
NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates
zacks.com
2025-10-28 09:16:10NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.05 per share a year ago.
NeoGenomics Reports Third Quarter 2025 Results
businesswire.com
2025-10-28 07:05:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its third-quarter results for the period ended September 30, 2025.
NEO Home Loans Appoints Bri Lees as Head of Marketing to Lead Brand and Growth Across Advisor-First Platform
businesswire.com
2025-10-23 09:00:00NEW YORK--(BUSINESS WIRE)-- #NEOHomeLoans--NEO Home Loans powered by Better (NASDAQ: BETR), has appointed Bri Lees as Head of Marketing, advancing the company's next phase of growth and deepening the connection between its advisor-led model and Better's digital platform. Lees will lead NEO's brand, communications, and marketing growth strategy—building the systems that connect how the company operates, shows up, and scales. Her focus is ensuring that the story and experience of working with NEO reflect the exc.
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
globenewswire.com
2025-10-20 08:01:00SYDNEY, AUSTRALIA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive data from the EFTISARC-NEO Phase II trial were shared in a Proffered Paper oral presentation by Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, at the 2025 European Society of Medical Oncology (ESMO) Congress in Berlin, Germany.
NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last?
zacks.com
2025-10-16 04:56:07NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
businesswire.com
2025-10-14 07:05:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will share at ESMO 2025 how its RaDaR ST MRD assay can support pharmaceutical partners across oncology research and clinical trials.
NeoGenomics to Present New ctDNA Research at SABCS 2025
businesswire.com
2025-12-10 07:05:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.
AerCap Signs Lease Agreements with New Customer My Freighter for Two New Airbus A321NEO Aircraft
prnewswire.com
2025-12-09 04:00:00DUBLIN , Dec. 9, 2025 /PRNewswire/ -- AerCap Holdings N.V. ("AerCap" or the "Company") (NYSE: AER) today announced it has signed lease agreements for two new Airbus A321neo aircraft with My Freighter, an Uzbekistan-based cargo airline that also operates charter and scheduled passenger services as Centrum Air.
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
businesswire.com
2025-12-08 08:05:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.
UK: TotalEnergies Merges Its Upstream Business with NEO NEXT, Creating the Largest Independent Oil and Gas Producer in the UK
businesswire.com
2025-12-08 03:08:00PARIS--(BUSINESS WIRE)--TotalEnergies has signed an agreement with NEO NEXT Energy Limited (NEO NEXT) under which TotalEnergies will merge its Upstream business with NEO NEXT and become the leading shareholder in the expanded NEO NEXT, which will be renamed NEO NEXT+, with a 47.5% ownership. After completion of the transaction, NEO NEXT+ will: be jointly owned by TotalEnergies (47.5%), HitecVision (28.875%) and Repsol UK (23.625%) and encompass a large and diverse asset portfolio including nota.
Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $13.11
defenseworld.net
2025-11-18 02:34:45Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) have earned an average rating of "Hold" from the sixteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company.
Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-14 12:41:31Neo Performance Materials Inc. ( NEO:CA ) Q3 2025 Earnings Call November 14, 2025 10:00 AM EST Company Participants Karen Murray Rahim Suleman - CEO, President & Director Jonathan Baksh - Executive VP & CFO Conference Call Participants Daniel Harriman - Sidoti & Company, LLC Nicholas Boychuk - Cormark Securities Inc., Research Division Ian Gillies - Stifel Nicolaus Canada Inc., Research Division Presentation Operator Good morning, and welcome to the Neo Performance Materials Third Quarter 2025 Earnings Conference Call. For opening remarks and introduction, let me turn the call over to Karen Murray, General Counsel for Neo.
NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)
globenewswire.com
2025-11-13 09:00:00CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial.
NeoGenomics to Participate in Upcoming Investor Conferences
businesswire.com
2025-11-06 07:05:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 37th Annual Healthcare Conference.
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
businesswire.com
2025-10-30 12:51:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research at ISLB 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 MRD assays, plus four additional posters.
NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-10-28 15:11:55NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Priya Vedaraman Anthony Zook - CEO & Director Jeffrey Sherman - Chief Financial Officer Warren Stone - President & COO Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Mason Carrico - Stephens Inc., Research Division Thomas Stevens - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Yuko Oku - Morgan Stanley, Research Division Puneet Souda - Leerink Partners LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Joseph Conway - Needham & Company, LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the NeoGenomics Third Quarter 2025 Financial Results Call.
NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates
zacks.com
2025-10-28 09:16:10NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.05 per share a year ago.
NeoGenomics Reports Third Quarter 2025 Results
businesswire.com
2025-10-28 07:05:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its third-quarter results for the period ended September 30, 2025.
NEO Home Loans Appoints Bri Lees as Head of Marketing to Lead Brand and Growth Across Advisor-First Platform
businesswire.com
2025-10-23 09:00:00NEW YORK--(BUSINESS WIRE)-- #NEOHomeLoans--NEO Home Loans powered by Better (NASDAQ: BETR), has appointed Bri Lees as Head of Marketing, advancing the company's next phase of growth and deepening the connection between its advisor-led model and Better's digital platform. Lees will lead NEO's brand, communications, and marketing growth strategy—building the systems that connect how the company operates, shows up, and scales. Her focus is ensuring that the story and experience of working with NEO reflect the exc.
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
globenewswire.com
2025-10-20 08:01:00SYDNEY, AUSTRALIA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive data from the EFTISARC-NEO Phase II trial were shared in a Proffered Paper oral presentation by Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, at the 2025 European Society of Medical Oncology (ESMO) Congress in Berlin, Germany.
NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last?
zacks.com
2025-10-16 04:56:07NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
businesswire.com
2025-10-14 07:05:00FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will share at ESMO 2025 how its RaDaR ST MRD assay can support pharmaceutical partners across oncology research and clinical trials.